During the past decade, Southeast Retina Center conducted 67 clinical trials. In the 10-year time frame, 67 clinical trials started and 33 clinical trials were completed, i.e. on average, 49.3% percent of trials that started reached the finish line to date. In the past 5 years, 38 clinical trials started and 24 clinical trials were completed. i.e. 63.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Southeast Retina Center" #1 sponsor was "Jaeb Center for Health Research" with 20 trials, followed by "Hoffmann-La Roche" with 17 trials sponsored, "Genentech, Inc." with 6 trials sponsored, "Southeast Retina Center, Georgia" with 6 trials sponsored and "Kodiak Sciences Inc" with 6 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Southeast Retina Center" #1 collaborator was "National Eye Institute (NEI)" with 19 trials as a collaborator, "Genentech, Inc." with 9 trials as a collaborator, "National Institutes of Health (NIH)" with 8 trials as a collaborator, "Regeneron Pharmaceuticals" with 5 trials as a collaborator and "Allergan" with 4 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Southeast Retina Center" are "Diabetic Macular Edema" (21 trials), "Macular Degeneration" (12 trials), "Diabetic Retinopathy" (10 trials), "Geographic Atrophy" (10 trials) and "Proliferative Diabetic Retinopathy" (5 trials). Many other conditions were trialed in "Southeast Retina Center" in a lesser frequency.

Most popular intervention types in "Southeast Retina Center" are "Drug" (77 trials), "Other" (18 trials), "Procedure" (15 trials), "Device" (8 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (15 trials), "Aflibercept" (12 trials), "Ranibizumab" (10 trials), "Faricimab" (9 trials) and "Placebo" (9 trials). Other intervention names were less common.

The vast majority of trials in "Southeast Retina Center" are 92 trials for "All" genders.

Currently, there are NaN active trials in "Southeast Retina Center". undefined are not yet recruiting, 9 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Southeast Retina Center, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Southeast Retina Center, 11 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 4 trials that are defined as “Not Applicable".